We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook
Read MoreHide Full Article
Key Takeaways
Merck raises 2026 sales guidance to $66.8-$67.3 billion as Q3 revenues rise 4.7% to $18.09 billion.
MRK's KEYTRUDA franchise sales grow 6% to $8.60 billion, while WINREVAIR revenues surge 93% to $694 million.
Merck expects modest 2027 growth amid over $2 billion in generic headwinds and rising pipeline investments.
Merck & Co., Inc. (MRK - Free Report) highlighted strong oncology demand, expanding contributions from newer medicines and significant clinical advancements during its third-quarter 2026 earnings call.
Management raised its full-year sales and earnings outlook while emphasizing progress in developing a diversified portfolio capable of supporting growth beyond KEYTRUDA's loss of exclusivity. However, executives cautioned that generic competition, vaccine market pressures and rising research expenditures could temper growth in 2027.
MRK Q3 Earnings Beat Zacks Estimates
Merck reported third-quarter 2026 non-GAAP earnings of $2.49 per share, surpassing the Zacks Consensus Estimate of $2.12 by 17.5%. However, earnings declined 3.5% year over year from $2.58 per share.
Revenues increased 4.7% year over year to $18.09 billion, exceeding the Zacks Consensus Estimate of $17.23 billion by approximately 5%. Excluding foreign exchange effects, sales increased 4%.
Merck & Co., Inc. Price, Consensus and EPS Surprise
GAAP earnings declined 12% year over year to $2.04 per share. Non-GAAP gross margin contracted 50 basis points to 81.4%, reflecting higher production costs. Non-GAAP research and development expenses increased 13% to $4.53 billion, due to pipeline investments and licensing charges.
KEYTRUDA and KEYTRUDA QLEX generated combined sales of $8.60 billion, up 6%, while WINREVAIR sales surged 93% to $694 million. Animal Health revenues increased 4% to $1.68 billion.
Merck Raises 2026 Revenue and Earnings Guidance
Chief financial officer Caroline Litchfield raised the lower end of Merck's 2026 revenue guidance to $66.8 billion from $66.3 billion, maintaining the upper end at $67.3 billion.
Management also increased non-GAAP earnings guidance to $2.77-$2.82 per share from $2.66-$2.76. The updated outlook includes a 12-cent-per-share charge related to the SciBrunch licensing agreement.
The company expects approximately 81% non-GAAP gross margin and operating expenses of $42.4 billion-$42.9 billion.
Litchfield noted that third-quarter revenues benefited from approximately $550 million in favorable customer purchase timing, including $200 million attributable to KEYTRUDA, $50 million to WINREVAIR and $300 million to vaccines.
Approximately $300 million of these benefits are expected to reverse in the fourth quarter, with the remaining $250 million reversing in 2027.
KEYTRUDA QLEX Adoption Gains Momentum
The KEYTRUDA franchise remained Merck's primary revenue driver, supported by expanding use in earlier-stage cancers and growing adoption of its subcutaneous formulation.
KEYTRUDA QLEX generated $830 million in third-quarter sales, with most revenues coming from the United States.
During questioning from Bernstein, CEO Robert Davis emphasized management's confidence in the company's intellectual property position despite ongoing European patent litigation.
Oncology president Jannie Oosthuizen reiterated Merck's objective of achieving 30%-40% adoption of subcutaneous KEYTRUDA in the United States by the end of 2027.
However, a temporary injunction has restricted supplies in several European countries, including France, Italy and the Netherlands. Management believes the impact on overall subcutaneous volumes remains immaterial.
Merck Highlights Breakthroughs in Oncology Pipeline
Merck emphasized positive Phase III results from its TroFuse-005 trial evaluating sacituzumab tirumotecan, or sac-TMT, in advanced or recurrent endometrial cancer.
The treatment reduced the risk of death by 32% compared with chemotherapy, with management highlighting an approximately seven-month improvement in median overall survival.
The FDA has accepted the application for priority review, with a target decision date of June 15, 2027.
Merck also reported encouraging results from its collaboration with Moderna on intismeran autogene, an individualized mRNA cancer vaccine.
The Phase III INTerpath-001 study demonstrated a 42% reduction in the risk of recurrence or death when intismeran was combined with KEYTRUDA compared with KEYTRUDA alone in certain patients with resected melanoma.
Research chief Dean Li highlighted opportunities to expand both programs across additional tumor types, including lung, bladder and renal cancers.
Merck Expects Modest Growth in 2027
During questioning from JPMorgan, Litchfield characterized 2027 as another significant investment year.
Management expects modest revenue growth, with new product launches and Animal Health contributions partly offset by more than $2 billion in headwinds from generic competition and patent expirations affecting BRIDION, JANUVIA and related products, and Adempas.
KEYTRUDA growth is also expected to moderate as penetration approaches peak levels in several approved indications.
Merck anticipates mid-to-high-single-digit growth in underlying operating expenses as it expands clinical development and commercial investments.
Despite these pressures, management expects the revenue decline associated with KEYTRUDA's eventual loss of exclusivity to be relatively shallow, followed by a return to growth.
Merck Sees Expanding Long-Term Revenue Opportunities
During questioning from Goldman Sachs, Davis expressed growing confidence in the company's previously outlined opportunity to generate more than $70 billion in annual revenues from its new and emerging portfolio by the mid-2030s.
He indicated that the potential could increase further, reflecting encouraging clinical developments and opportunities not fully incorporated into earlier projections.
The Terns Pharmaceuticals acquisition, PD-1/VEGF bispecific program and broader potential applications for sac-TMT could provide additional growth.
Davis also highlighted stronger-than-expected commercial potential for intismeran following positive clinical results.
Management believes these developments strengthen Merck's ability to offset the eventual KEYTRUDA patent-expiration headwind.
MRK's Newer Products Support Portfolio Diversification
Beyond oncology, Merck highlighted continued momentum across its expanding commercial portfolio.
WINREVAIR revenues reached $694 million, supported by increasing demand for pulmonary arterial hypertension treatment. The company also reported $184 million in OHTUVAYRE revenues.
During questioning from TD Cowen, Specialty Pharma President Brian Foard disclosed that LIPFENDRA generated more than 11,000 prescriptions during the quarter from over 6,500 prescribers.
Management expects broader commercial insurance access in 2027 and Medicare access in 2028, positioning the cholesterol treatment as a potential multibillion-dollar opportunity.
Merck also highlighted positive Phase IIb results for tulisokibart in hidradenitis suppurativa and encouraging ophthalmology data for remigromig.
These developments reinforce the company's strategy to diversify beyond oncology while establishing additional long-term revenue streams.
Key Takeaways for MRK Investors
Merck's third-quarter performance demonstrated resilient pharmaceutical demand and improving contributions from newer medicines, with earnings and revenues exceeding Zacks expectations.
The increased 2026 outlook and encouraging clinical results provide support for management's long-term growth strategy.
However, near-term challenges remain, including slowing KEYTRUDA growth, generic competition, elevated research spending and uncertainty surrounding the commercialization of pipeline assets.
With a Zacks Rank #5 (Strong Sell), Merck's improving pipeline prospects must be weighed against the earnings pressures associated with its ongoing portfolio transformation. The company has a Value Score of D, a Growth Score of B, a Momentum Score of A and a VGM Score of C.
View the Zacks #1 Rank List
Image: Bigstock
Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook
Key Takeaways
Merck & Co., Inc. (MRK - Free Report) highlighted strong oncology demand, expanding contributions from newer medicines and significant clinical advancements during its third-quarter 2026 earnings call.
Management raised its full-year sales and earnings outlook while emphasizing progress in developing a diversified portfolio capable of supporting growth beyond KEYTRUDA's loss of exclusivity. However, executives cautioned that generic competition, vaccine market pressures and rising research expenditures could temper growth in 2027.
MRK Q3 Earnings Beat Zacks Estimates
Merck reported third-quarter 2026 non-GAAP earnings of $2.49 per share, surpassing the Zacks Consensus Estimate of $2.12 by 17.5%. However, earnings declined 3.5% year over year from $2.58 per share.
Revenues increased 4.7% year over year to $18.09 billion, exceeding the Zacks Consensus Estimate of $17.23 billion by approximately 5%. Excluding foreign exchange effects, sales increased 4%.
Merck & Co., Inc. Price, Consensus and EPS Surprise
Merck & Co., Inc. price-consensus-eps-surprise-chart | Merck & Co., Inc. Quote
GAAP earnings declined 12% year over year to $2.04 per share. Non-GAAP gross margin contracted 50 basis points to 81.4%, reflecting higher production costs. Non-GAAP research and development expenses increased 13% to $4.53 billion, due to pipeline investments and licensing charges.
KEYTRUDA and KEYTRUDA QLEX generated combined sales of $8.60 billion, up 6%, while WINREVAIR sales surged 93% to $694 million. Animal Health revenues increased 4% to $1.68 billion.
Merck Raises 2026 Revenue and Earnings Guidance
Chief financial officer Caroline Litchfield raised the lower end of Merck's 2026 revenue guidance to $66.8 billion from $66.3 billion, maintaining the upper end at $67.3 billion.
Management also increased non-GAAP earnings guidance to $2.77-$2.82 per share from $2.66-$2.76. The updated outlook includes a 12-cent-per-share charge related to the SciBrunch licensing agreement.
The company expects approximately 81% non-GAAP gross margin and operating expenses of $42.4 billion-$42.9 billion.
Litchfield noted that third-quarter revenues benefited from approximately $550 million in favorable customer purchase timing, including $200 million attributable to KEYTRUDA, $50 million to WINREVAIR and $300 million to vaccines.
Approximately $300 million of these benefits are expected to reverse in the fourth quarter, with the remaining $250 million reversing in 2027.
KEYTRUDA QLEX Adoption Gains Momentum
The KEYTRUDA franchise remained Merck's primary revenue driver, supported by expanding use in earlier-stage cancers and growing adoption of its subcutaneous formulation.
KEYTRUDA QLEX generated $830 million in third-quarter sales, with most revenues coming from the United States.
During questioning from Bernstein, CEO Robert Davis emphasized management's confidence in the company's intellectual property position despite ongoing European patent litigation.
Oncology president Jannie Oosthuizen reiterated Merck's objective of achieving 30%-40% adoption of subcutaneous KEYTRUDA in the United States by the end of 2027.
However, a temporary injunction has restricted supplies in several European countries, including France, Italy and the Netherlands. Management believes the impact on overall subcutaneous volumes remains immaterial.
Merck Highlights Breakthroughs in Oncology Pipeline
Merck emphasized positive Phase III results from its TroFuse-005 trial evaluating sacituzumab tirumotecan, or sac-TMT, in advanced or recurrent endometrial cancer.
The treatment reduced the risk of death by 32% compared with chemotherapy, with management highlighting an approximately seven-month improvement in median overall survival.
The FDA has accepted the application for priority review, with a target decision date of June 15, 2027.
Merck also reported encouraging results from its collaboration with Moderna on intismeran autogene, an individualized mRNA cancer vaccine.
The Phase III INTerpath-001 study demonstrated a 42% reduction in the risk of recurrence or death when intismeran was combined with KEYTRUDA compared with KEYTRUDA alone in certain patients with resected melanoma.
Research chief Dean Li highlighted opportunities to expand both programs across additional tumor types, including lung, bladder and renal cancers.
Merck Expects Modest Growth in 2027
During questioning from JPMorgan, Litchfield characterized 2027 as another significant investment year.
Management expects modest revenue growth, with new product launches and Animal Health contributions partly offset by more than $2 billion in headwinds from generic competition and patent expirations affecting BRIDION, JANUVIA and related products, and Adempas.
KEYTRUDA growth is also expected to moderate as penetration approaches peak levels in several approved indications.
Merck anticipates mid-to-high-single-digit growth in underlying operating expenses as it expands clinical development and commercial investments.
Despite these pressures, management expects the revenue decline associated with KEYTRUDA's eventual loss of exclusivity to be relatively shallow, followed by a return to growth.
Merck Sees Expanding Long-Term Revenue Opportunities
During questioning from Goldman Sachs, Davis expressed growing confidence in the company's previously outlined opportunity to generate more than $70 billion in annual revenues from its new and emerging portfolio by the mid-2030s.
He indicated that the potential could increase further, reflecting encouraging clinical developments and opportunities not fully incorporated into earlier projections.
The Terns Pharmaceuticals acquisition, PD-1/VEGF bispecific program and broader potential applications for sac-TMT could provide additional growth.
Davis also highlighted stronger-than-expected commercial potential for intismeran following positive clinical results.
Management believes these developments strengthen Merck's ability to offset the eventual KEYTRUDA patent-expiration headwind.
MRK's Newer Products Support Portfolio Diversification
Beyond oncology, Merck highlighted continued momentum across its expanding commercial portfolio.
WINREVAIR revenues reached $694 million, supported by increasing demand for pulmonary arterial hypertension treatment. The company also reported $184 million in OHTUVAYRE revenues.
During questioning from TD Cowen, Specialty Pharma President Brian Foard disclosed that LIPFENDRA generated more than 11,000 prescriptions during the quarter from over 6,500 prescribers.
Management expects broader commercial insurance access in 2027 and Medicare access in 2028, positioning the cholesterol treatment as a potential multibillion-dollar opportunity.
Merck also highlighted positive Phase IIb results for tulisokibart in hidradenitis suppurativa and encouraging ophthalmology data for remigromig.
These developments reinforce the company's strategy to diversify beyond oncology while establishing additional long-term revenue streams.
Key Takeaways for MRK Investors
Merck's third-quarter performance demonstrated resilient pharmaceutical demand and improving contributions from newer medicines, with earnings and revenues exceeding Zacks expectations.
The increased 2026 outlook and encouraging clinical results provide support for management's long-term growth strategy.
However, near-term challenges remain, including slowing KEYTRUDA growth, generic competition, elevated research spending and uncertainty surrounding the commercialization of pipeline assets.
With a Zacks Rank #5 (Strong Sell), Merck's improving pipeline prospects must be weighed against the earnings pressures associated with its ongoing portfolio transformation. The company has a Value Score of D, a Growth Score of B, a Momentum Score of A and a VGM Score of C.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.